Psivida and Solbec granted US patents

Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has been granted its fifth US patent for the classification of porous silicon into monodispersed particles with a tight size distribution.

The patent covers additional dimensions in the formulation of drug delivery products and provides for the accurate definition of Psivida's BioSilicon particle size and distribution, allowing better control of biodegradation. The classification into defined size distributions is a key attribute of many micro-engineered particle products.

Solbec Pharmaceuticals (ASX:SBP) has also been granted a US patent entitled 'Rhamnose Binding Protein' (RBP) which gives the company the monopoly right to prevent others from isolating RBP for the purpose of generating compounds, including diagnostic and therapeutic compounds, that target the protein.

The RBP receptor is over-expressed in mammalian cancer cells, but not in healthy cells, and explains why Solbec's Coramsine is selective in targeting cancer cells.

The patent describes and claims an isolated RMP which is insoluble in aqueous solutions and has a molecular weight of approximately 65-70 kDalton.

The patent runs until March 1, 2023 and is the first in a continuation of US patent filings made by Solbec related to RBP.